Lactoylglutathione lyase mRNA (Glyoxalase 1 mRNA) (GLO1 mRNA)

Lactoylglutathione lyase mRNA (GLO1 mRNA) is the transcript responsible for producing the Glyoxalase 1 enzyme, a critical component of the glyoxalase system that detoxifies methylglyoxal (MG), a reactive byproduct of glycolysis (UniProt, Q04760). In many human cancers, GLO1 mRNA is significantly upregulated, often through gene amplification, to protect tumor cells from MG-induced proteotoxic stress and apoptosis (PubMed, 24631451). By targeting the mRNA transcript using RNA interference (RNAi) or antisense oligonucleotides (ASOs), researchers aim to deplete GLO1 protein levels, thereby triggering selective cell death in high-glycolytic tumors (PubMed, 30107179). Beyond oncology, GLO1 expression is linked to the development of diabetic complications, where insufficient GLO1 activity leads to the accumulation of advanced glycation end-products (AGEs) (PubMed, 21835911). Furthermore, GLO1 mRNA levels in the brain have been associated with anxiety-related phenotypes, as MG acts as a competitive antagonist at GABA-A receptors (PubMed, 16244650). Therapeutic modulation of GLO1 mRNA offers a precise approach to controlling MG levels, though challenges remain regarding the systemic toxicity of MG and the delivery of RNA-based drugs (PubMed, 28652154).

Other names

GLO1GLY1Glyoxalase I mRNALactoylglutathione lyaseMethylglyoxalase mRNAAldoketomutase mRNA

RNA interference (RNAi) and antisense-mediated mRNA degradation leading to reduced protein expression and subsequent accumulation of toxic methylglyoxal.